Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Merck KGaA will pay Threshold Pharmaceuticals $25 million up front and up to $525 million in milestones for access to the cancer treatment TH-302. Merck will also cover 70% of the development costs for TH-302, a small molecule that is activated in tumor cell environments where the oxygen concentration is low. A Phase III trial testing the compound in soft-tissue sarcoma is under way, and Threshold expects to reveal data from a Phase II trial in pancreatic cancer later this month. Threshold retains an option to jointly sell the drug in the U.S.
This article has been sent to the following recipient: